HC Wainwright reaffirmed their hold rating on shares of Trevena (NASDAQ:TRVN) in a report issued on Thursday. HC Wainwright currently has a $1.25 price objective on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research upgraded shares of Trevena from a hold rating to a buy rating and set a $1.50 target price for the company in a research note on Thursday, February 7th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Trevena currently has a consensus rating of Buy and a consensus target price of $5.63.

NASDAQ TRVN traded up $0.04 during trading on Thursday, reaching $1.50. The company’s stock had a trading volume of 24,473 shares, compared to its average volume of 4,247,232. The company has a quick ratio of 4.30, a current ratio of 4.30 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $118.55 million, a PE ratio of -1.25 and a beta of 2.61. Trevena has a 1-year low of $0.38 and a 1-year high of $3.58.

Trevena (NASDAQ:TRVN) last posted its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.04). The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $3.00 million. As a group, equities analysts anticipate that Trevena will post -0.37 EPS for the current year.

In other news, CEO Maxine Gowen purchased 50,000 shares of the company’s stock in a transaction dated Friday, February 1st. The shares were bought at an average price of $1.02 per share, with a total value of $51,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Leon O. Moulder, Jr. purchased 100,000 shares of the company’s stock in a transaction dated Friday, February 1st. The stock was purchased at an average cost of $1.02 per share, for a total transaction of $102,000.00. The disclosure for this purchase can be found here. Company insiders own 4.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Trevena by 29.2% in the third quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after purchasing an additional 592,152 shares during the period. Vanguard Group Inc raised its position in shares of Trevena by 29.2% in the third quarter. Vanguard Group Inc now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after purchasing an additional 592,152 shares during the period. BlackRock Inc. raised its position in shares of Trevena by 151.4% in the third quarter. BlackRock Inc. now owns 1,873,311 shares of the biopharmaceutical company’s stock valued at $3,971,000 after purchasing an additional 1,128,041 shares during the period. Renaissance Technologies LLC increased its position in Trevena by 67.2% during the third quarter. Renaissance Technologies LLC now owns 872,300 shares of the biopharmaceutical company’s stock worth $1,849,000 after acquiring an additional 350,600 shares during the period. Finally, JPMorgan Chase & Co. increased its position in Trevena by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock worth $1,147,000 after acquiring an additional 80,437 shares during the period. 24.22% of the stock is currently owned by institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Read More: What is the NASDAQ Stock Market?

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.